European Archives - Page 397 of 1103 - European Medical Journal

Moving the needle on equal pay

Sabine Hutchison, CEO, Seuss+, and Operating Board President, EMEA, The Healthcare Businesswomen’s Association, discusses the legislation, challenges and hopes for closing the pay gap in life sciences.

EMJ Urology 11.1 2023 feature image

⁶⁸Ga-Prostate-Specific Membrane Antigen PET Radiomics For the Prediction of Post-Surgical International Society of Urological Pathology Grade in Patients with Primary Prostate Cancer

Radiomics has been proven effective for the characterisation of primary prostate cancer (PCa).1,2 However, the limited interpretability of the proposed models represents one of the major limitations in this field.

EMJ Urology 11.1 2023 feature image

EMJ Urology 11.1 2023

We are proud to present the latest issue of EMJ Urology! Included in this edition are the most recent developments in this specialty. You can find interviews with leading experts alongside peer-reviewed articles and the scientific highlights from the annual European Association of Urology (EAU) 2023 meeting which took place in Milan, Italy.

EAU Congress Interview: Arnulf Stenzl

A large part of urology is uro-oncology, so let’s start here. We have seen a minimalisation of surgery, so we are doing more robotic surgery and are trying to preserve more organs. For example, in renal cell cancer, we try to spare the kidney if possible and be minimally invasive.

Interview: Denis Poddubnyy

Interview: Denis Poddubnyy

Androgen Deprivation Therapy: Challenges and Future Perspective

This article details the use of androgen deprivation therapy in current clinical practice as discussed in an Accord Healthcare-sponsored symposium, delivered as part of the European Association of Urology (EAU) 38th Annual Congress held in Milan, Italy, between 10th–13th March 2023.

EMJ Urology 11.1 2023 feature image

SuPARnostic: An Advanced Predictive Tool for Detecting Recurrence in Renal Cell Carcinoma

Renal cell carcinoma (RCC) is the most common malignant kidney tumour, with clear cell RCC (ccRCC) accounting for 70–80% of all cases. Approximately 15–20% of patients have primary metastatic RCC at diagnosis, and 15–20% of those who receive curative treatment for localised tumours will experience recurrence within 5 years of follow-up.

EMJ Urology 11.1 2023 feature image

Genomic Profiling of Urothelial Carcinoma in Situ of the Bladder

Urothelial carcinoma in situ (CIS) of the bladder is an intra-epithelial, high grade, malignant neoplasm characterised by flat (non-papillary) growth, with high probability of disease progression.

5 minutes with Emma Chaffin, former Vice President, Country Head and Site Lead, Galapagos

Pharma leader Emma Chaffin talks about leaving pharmacy for the pharma and a key challenge facing her function.

Getting to the heart of synthetic data

Synthetic data can streamline clinical trials and enable ideas to be tested without draining R&D budgets. Read more about pros and cons of this approach.